Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

[Spectrum of psoriatic conditions].

Pouw JN, Leijten EFA, Tekstra J, Balak DMW, Radstake TRDJ.

Ned Tijdschr Geneeskd. 2019 Jul 29;163. pii: D3936. Dutch.

PMID:
31361418
2.

Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?

van der Schaft J, Thijs JL, de Bruin-Weller MS, Balak DMW.

Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):341-349. doi: 10.1097/ACI.0000000000000551.

PMID:
31145194
3.

In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine.

Xu M, Deng J, Xu K, Zhu T, Han L, Yan Y, Yao D, Deng H, Wang D, Sun Y, Chang C, Zhang X, Dai J, Yue L, Zhang Q, Cai X, Zhu Y, Duan H, Liu Y, Li D, Zhu Y, Radstake TRDJ, Balak DMW, Xu D, Guo T, Lu C, Yu X.

Theranostics. 2019 Apr 13;9(9):2475-2488. doi: 10.7150/thno.31144. eCollection 2019.

4.

Towards personalized treatment in atopic dermatitis.

van der Schaft J, Thijs JL, Garritsen FM, Balak D, de Bruin-Weller MS.

Expert Opin Biol Ther. 2019 May;19(5):469-476. doi: 10.1080/14712598.2019.1583204. Epub 2019 Feb 26.

PMID:
30768375
5.

More on Mu-Opioid Receptor Antagonists in PD-1 Blockade–Induced Pruritus.

Balak DMW, Hajdarbegovic E.

N Engl J Med. 2019 Feb 7;380(6):601. doi: 10.1056/NEJMc1815143. No abstract available.

PMID:
30730693
6.

Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017.

van der Kraaij GE, Balak DMW, Busard CI, van Cranenburgh OD, Chung Y, Driessen RJB, de Groot M, de Jong EMGJ, Kemperman PMJH, de Kort WJA, Karsch SA, Lamberts A, Lecluse LLA, van Lümig PPM, Menting SP, Prens EP, van den Reek JMPA, Seyger MMB, Thio HB, Veldkamp WR, Wakkee M, Nast A, Jacobs A, Rosumeck S, Spuls Chair PI.

Br J Dermatol. 2019 Jan;180(1):31-42. doi: 10.1111/bjd.17198. No abstract available.

PMID:
30604536
7.

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.

Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, van Wijk F, Knol EF, Balak DMW, van Dijk MR, de Bruin-Weller MS.

Br J Dermatol. 2019 May;180(5):1248-1249. doi: 10.1111/bjd.17538. Epub 2019 Feb 4. No abstract available.

PMID:
30597515
8.

Topical trifarotene: a new retinoid.

Balak DMW.

Br J Dermatol. 2018 Aug;179(2):231-232. doi: 10.1111/bjd.16733. No abstract available.

PMID:
30141539
9.

Drug-induced psoriasis: clinical perspectives.

Balak DM, Hajdarbegovic E.

Psoriasis (Auckl). 2017 Dec 7;7:87-94. doi: 10.2147/PTT.S126727. eCollection 2017. Review.

10.

First-line systemic treatment of psoriasis: staying conventional or going biologic?

Balak DMW.

Br J Dermatol. 2017 Oct;177(4):897-898. doi: 10.1111/bjd.15885. No abstract available.

PMID:
29052873
11.

Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.

Hajdarbegovic E, Balak DM.

N Engl J Med. 2017 May 25;376(21):2092. doi: 10.1056/NEJMc1704013. No abstract available.

PMID:
28541012
12.

Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.

Balak DMW, Hajdarbegovic E, Bramer WM, Neumann HAM, Thio HB.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1475-1482. doi: 10.1111/jdv.14236. Epub 2017 Apr 25.

PMID:
28322482
13.

Dimethyl fumarate finally coming of age.

Balak DM.

Br J Dermatol. 2017 Mar;176(3):563-564. doi: 10.1111/bjd.15330. No abstract available.

PMID:
28300316
14.

A 28-Year-Old Male Patient with Nail Tumors, Skin Lesions, and Epilepsy.

Balak DM, Zonnenberg BA, Spitzer-Naaijkens JM, Hulshof MM.

Case Rep Dermatol. 2017 Jan 26;9(1):12-19. doi: 10.1159/000455037. eCollection 2017 Jan-Apr.

15.

Percutaneous ligature of the superficial temporal artery: A simple technique to reduce bleeding.

Hajdarbegovic E, Balak D.

J Am Acad Dermatol. 2017 Jan;76(1):e15. doi: 10.1016/j.jaad.2016.06.039. No abstract available.

PMID:
27986152
16.

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.

Balak DM, van Doorn MB, Arbeit RD, Rijneveld R, Klaassen E, Sullivan T, Brevard J, Thio HB, Prens EP, Burggraaf J, Rissmann R.

Clin Immunol. 2017 Jan;174:63-72. doi: 10.1016/j.clim.2016.09.015. Epub 2016 Nov 20.

PMID:
27876460
17.

Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study.

van Bezooijen JS, Balak DM, van Doorn MB, Looman CW, Schreurs MW, Koch BC, van Gelder T, Prens EP.

Dermatology. 2016;232(4):407-14. doi: 10.1159/000448135. Epub 2016 Sep 1.

18.

Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies.

Balak DM, Fallah Arani S, Hajdarbegovic E, Hagemans CA, Bramer WM, Thio HB, Neumann HA.

Br J Dermatol. 2016 Aug;175(2):250-62. doi: 10.1111/bjd.14500. Epub 2016 Jul 19. Review.

PMID:
26919824
19.

Drug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case series.

Balak DM, Bouwes Bavinck JN, de Vries AP, Hartman J, Neumann HA, Zietse R, Thio HB.

Clin Kidney J. 2016 Feb;9(1):82-9. doi: 10.1093/ckj/sfv114. Epub 2015 Nov 10.

20.

More on PML in Patients Treated with Dimethyl Fumarate. Author reply.

Balak D, Hajdarbegovic E.

N Engl J Med. 2016 Jan 21;374(3):295. doi: 10.1056/NEJMc1512228. No abstract available.

PMID:
26789899

Supplemental Content

Support Center